Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Treatment outcomes of advanced digestive well-differentiated grade 3 NETs (2021) de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AM, et al. Journal article The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents (2021) Dürr P, Schlichtig K, Kelz C, Deutsch B, Maas R, Eckart MJ, Wilke J, et al. Journal article Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3) (2021) Apostolidis L, Dal Buono A, Merola E, Jann H, Jaeger D, Wiedenmann B, Winkler EC, Pavel ME Journal article Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Journal article, Review article Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) - USA and Canada vs Global Diagnosis of NETs (2021) Gellerman E, Herman J, Mcdonnell M, Van Genechten D, Pavel ME, O'Toole D, Singh H, et al. Conference contribution Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (2021) Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms (2021) Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, et al. Journal article Consensus on molecular imaging and theranostics in neuroendocrine neoplasms (2021) Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, et al. Journal article, Review article Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results (2021) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Thanh TXM, et al. Conference contribution Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Conference contribution